Home > Newsletters > FDAnews Drug Daily Bulletin > AC Immune Raises CHF 21 Million in Private Financing Round
FDAnews Drug Daily Bulletin
May 12, 2005 | Vol. 2 No. 94
AC Immune Raises CHF 21 Million in Private Financing Round
AC Immune, a Swiss biotech company developing innovative therapies against Alzheimer's disease, announced that it has successfully completed its round B financing raising CHF 21 million from private and strategic investors. The financing goal of CHF 21 millions was achieved with two-thirds of the invested capital contributed by new investors. AC immune is focused on new therapies for the treatment of Alzheimer's disease using vaccination or passive immunization with antibodies.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.